News 2024
News list
-
New Partner Starlab Space at the Innovation Park Zurich
A new ecosystem in which space experts, researchers, scientists, established industries, innovative start-ups, and spin-offs work closely together.
-
DIZH Structure Call: Five projects by UZH members funded
Five projects are being funded in the 2nd structure call of the DIZH Innovation Program.
-
EPO Study reveals: Switzerland ranks 2nd in Europe for Patents Per Capita
Switzerland once again demonstrates its innovative prowess, ranking second in Europe for patents per capita, according to a new study from the European Patent Office (EPO).
-
Innovathon 2024: Swisscom Team «Diverse Stereotypes» triumphs in Mobility Challenge
This year, the Innovathon 2024 "The Digitalization of Mobility" pitch brought together seven inventive student teams to present their cutting-edge solutions aimed at transforming mobility.
-
UZH Spin-off Saiba Animal Health is acquired by Boehringer Ingelheim
Boehringer Ingelheim is acquiring Saiba Animal Health, a UZH spin-off focused on developing novel therapeutic medicines for the treatment of chronic diseases in companion animals.
-
UZH Spin-off success in the TOP 100 Swiss Startup Ranking
The TOP 100 Swiss Startup Ranking showcases the 100 Swiss startups with the greatest potential. Take a look at the success of UZH Spin-offs.
-
OxyPrem – call to protect the weakest patients
OxyPrem has developed a technology specifically designed to monitor oxygen levels in premature babies.
-
UZH Space Hub provides momentum for the space economy
The Space Hub at the University of Zurich recently opened its doors to aerospace start-ups at the Innovation Park in Zurich.
-
ONtrack Biomedical AG has been awarded the UZH Startup Label
ONtrack Biomedical AG is a UZH MedTech company that develops in-vitro diagnostic tests for the non-invasive early detection and monitoring of prostate cancer. ONtrack Biomedical was awarded the UZH Startup Label in 2024.
-
UZH spin-off successfully closes a financing
Synthara successfully closes a financing round of over USD 11 million.
-
DIZH Rapid-Action-Call: Funded Projects
In the 3rd Rapid-Action-Call of the DIZH Innovation Program, 6 projects are being funded, 5 with team members of UZH.
-
UZH Spin-off has won the leading Swiss startup competition 2024
Kevin Yim wins with EVIIVE the first place in Switzerland's leading start-up competition >>venture>>, which recognizes the best business ideas and business plans in Switzerland.
-
Boosting Talents – Annual Report 2023
The Innovation Hub's 2023 annual report provides an overview of innovation activities at UZH as well as inspiring stories – take a look.
-
TOP 100 Swiss Startup Award
The public voting for TOP 100 Swiss Startups is your chance to highlight an excellent Swiss startup. Please vote for entrepreneurs from the University of Zurich!
-
Innovators Camp 2024 – successful Social Innovators
Over 20 participants responded to the call «Are you motivated to make a positive social impact?» and worked in interdisciplinary groups to develop digital solutions to current issues.
-
Biotech company opts for UZH spin-off Oncobit
Oncobit, founded in 2018 as a UZH spin-off, announces partnership with Immunocore to advance therapy response analysis in clinical trials.
-
FimmCyte funded by the UZH Life Science Fund
The UZH Life Science Fund awards CHF 1 million for FimmCyte.
-
Innovator Mornings – Exchange among innovators
Interview with Josua Jordi, CEO and co-founder of EraCal at the Innovator Mornings
-
Nextcasts – From lab to market: Unlocking Innovation at Universities
The Deputy Head Innovation Office at the University of Zurich, Eva Maria Håkanson talks on the Swissnex San Francisco Podcast about moving ideas from the university to market.
-
Sparkling Research: Honoring UZH Entrepreneur Fellows
The Vice-Rector for Research, Prof. Elisabeth Stark awarded certificates to Simon Bredl, Simon Gruening and Kevin Yim for their successful completion of the UZH Entrepreneur Fellowship program in 2023.
-
UZH spin-off new partnering deal
Congratulations to UZH spin-off EraCal Therapeutics to their new partnering deal with Novo Nordisk. This is a huge step foward for the start-up, with a potential value of EUR 235 million, and brings revolutionary therapy for obesity one step closer to the market.
-
Spin-off for immunotherapy
UZH researchers have co-founded Seito Biologics AG to develop a new treatment for autoimmunty. After several years of research at the Department of Immunology of the University of Zurich, the team is now ready to take the next step with their approach, which is based on selective Treg cell engagers (TREX).